<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753037</url>
  </required_header>
  <id_info>
    <org_study_id>Mayo-06-004680</org_study_id>
    <nct_id>NCT01753037</nct_id>
  </id_info>
  <brief_title>Effects of Androgen Administration on Inflammation in Normal Women</brief_title>
  <official_title>Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that DHEA administration to increase male hormone in healthy&#xD;
      normal-weight young women to levels present in women with Polycystic Ovary Syndrome will&#xD;
      cause an inflammatory response in white blood cells in the fasting state, and in response to&#xD;
      glucose ingestion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nuclear factor kappa B (NFkappaB) activation</measure>
    <time_frame>0 and 2 hours after glucose ingestion</time_frame>
    <description>White blood cell NFkappaB activation will be assessed in response to glucose ingestion before and after 5 days of DHEA or placebo administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>0 and 5 days after DHEA or placebo</time_frame>
    <description>Insulin sensitivity derived from an oral glucose tolerance test (OGTT) will be assessed before and after 5 days of DHEA or placebo administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hyperandrogenism</condition>
  <arm_group>
    <arm_group_label>DHEA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of an identical capsule containing placebo for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dehydroepiandrosterone (DHEA)</intervention_name>
    <description>DHEA 130 mg administered orally for 5 days.</description>
    <arm_group_label>DHEA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acceptable health based on interview, medical history, physical examination and lab&#xD;
             tests&#xD;
&#xD;
          -  Ability to comply with requirements of the study&#xD;
&#xD;
          -  Ability and willingness to provide signed, witnessed informed consent&#xD;
&#xD;
          -  Between the ages of 18-40 years&#xD;
&#xD;
          -  Body mass index between 18 and 25&#xD;
&#xD;
          -  Normal regular monthly periods&#xD;
&#xD;
          -  No clinical evidence of androgen excess&#xD;
&#xD;
          -  No evidence of polycystic ovaries on ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric,&#xD;
             infectious and malignant disease&#xD;
&#xD;
          -  High blood pressure&#xD;
&#xD;
          -  Current or recent (within 30 days prior to study entry) use of any drugs known or&#xD;
             suspected to affect reproductive function including oral contraceptives, metformin,&#xD;
             gonadotropin releasing hormone agonists, or anti-androgens (spironolactone, flutamide,&#xD;
             etc.)&#xD;
&#xD;
          -  Use of medications that have an adverse drug interaction with DHEA therapy including&#xD;
             antipsychotics, phenothiazines, lithium, selective serotonin reuptake inhibitors,&#xD;
             triazolam, estrogen or testosterone formulations&#xD;
&#xD;
          -  Known hypersensitivity to DHEA&#xD;
&#xD;
          -  Two first-degree relatives with breast cancer or ovarian cancer&#xD;
&#xD;
          -  Documented or suspected history of recent (within 1 year) illicit drug abuse or&#xD;
             alcoholism&#xD;
&#xD;
          -  Tobacco smoking&#xD;
&#xD;
          -  Ingestion of any investigational drugs within 4 weeks prior to study onset&#xD;
&#xD;
          -  Pregnancy or lactation (less than or equal to 6 weeks postpartum)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Gonz√°lez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 15, 2012</study_first_submitted>
  <study_first_submitted_qc>December 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Frank Gonzalez</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hyperandrogenism</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperandrogenism</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

